$5.88 Billion is the total value of Avoro Capital Advisors LLC's 41 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 60.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $114,781,000 | -43.7% | 1,235,000 | -63.9% | 1.95% | -39.0% |
| PMVP | Sell | PMV PHARMACEUTICALS INC | $33,842,000 | -61.2% | 1,465,000 | -49.9% | 0.58% | -57.9% |
| Sell | NUVALENT INC | $18,431,000 | -17.3% | 1,102,671 | -12.3% | 0.31% | -10.3% | |
| Sell | DICE THERAPEUTICS INC | $14,237,000 | -45.7% | 562,500 | -29.7% | 0.24% | -41.3% | |
| AVDL | Sell | AVADEL PHARMACEUTICALS PLCsponsored adr | $13,494,000 | -39.5% | 1,670,000 | -26.6% | 0.23% | -34.3% |
| FENC | Sell | FENNEC PHARMACEUTICALS INC | $5,280,000 | -66.4% | 1,200,000 | -28.1% | 0.09% | -63.6% |
| XLRN | Exit | ACCELERON PHARMA INCcall | $0 | – | -476,100 | -100.0% | -0.00% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INCcall | $0 | – | -1,515,000 | -100.0% | -0.02% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INCcall | $0 | – | -650,000 | -100.0% | -0.02% | – |
| MRUS | Exit | MERUS N V | $0 | – | -450,000 | -100.0% | -0.16% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -84,000 | -100.0% | -0.37% | – |
| DCPH | Exit | DECIPHERA PHARMACEUTICALS INC | $0 | – | -1,068,000 | -100.0% | -0.57% | – |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -5,700,000 | -100.0% | -1.57% | – | |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -664,000 | -100.0% | -1.89% | – |
| XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -4,000,000 | -100.0% | -10.81% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.